Global Pricing Innovations
There is no excerpt because this is a protected post.
Read MoreLoss of exclusivity is the biggest risk to your drug’s revenue stream. But it doesn’t have to be.
Read MoreThere is no excerpt because this is a protected post.
Read MoreAt GPI, our work is centred around our FOUR core values: Quality Matters, Sustainability, Authenticity and Collaboration. Every day, our amazing staff go above and beyond for our customers and strive to maintain the high quality standards and values that GPI stands for.
Read MoreMinimising uncertainty for biopharmaceutical payers and manufacturers is a key factor in maximising pricing and market access of orphan drugs.
Read MoreCell and gene therapies (CGTs) offer potential curative and restorative treatments for previously untreatable diseases. This comes at an extremely high cost with some CGTs exceeding one million Euros.
Read MoreThe launch of new medicines is a complex process that requires careful consideration of pricing and reimbursement strategies. This webinar will provide an overview of the mechanisms of pricing and reimbursement that are essential to ensure the successful launch and uptake of new medicines.
Read MoreAt GPI, our work is centred around our FOUR core values: Quality Matters, Sustainability, Authenticity and Collaboration. Every day, our amazing staff go above and beyond for our customers and strive to maintain the high quality standards and values that GPI stands for.
Read MoreTraditional pricing and market access research activities provide insights during a snapshot of your assets journey. Learn how we use payer behaviour analytics to define the relationship between value and price, providing a robust and flexible alternative to determine a value-based price for a new asset.
Read More